Bristol Myers Squibb presents data across targeted protein degradation research at EHA 2025

Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies

Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease

Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression

Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development

The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities

NVIDIA partners with Novo Nordisk and DCAI to advance drug discovery

The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development

Bristol Myers Squibb announces positive results from Phase 3 Poetyk PsA-1 and PsA-2 trials of deucravacitinib in psoriatic arthritis

FDA approves AbbVie’s mavyret as first and only treatment for acute hepatitis C

Now approved for both acute and chronic HCV in adults and children aged 3 and above

Mezzion secures $20 million funding to advance Phase 3 clinical development of Udenafil for fontan patients

Sigachi Industries gets ToR approval for API and specialty chemicals manufacturing facility in Andhra Pradesh

The project will be instrumental in enhancing the company's API manufacturing capacity and global reach

IOL Chemicals and Pharmaceuticals bags EcoVadis silver medal

Ranks among the top 15% companies globally

Sun Pharma appoints Kirti Ganorkar as the Managing Director

Dilip Shanghvi to continue as the Executive Chairman of the Board